Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | BACE1 | P56817 | 2/20 | 0.33 |
| ▸ | REN | P00797 | 3/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10009462 | 1.00 | ADRB3 (0.43) | ADRB3ADRA2BADRA2CCYP3A4BACE1 | |
| SCHEMBL12792428 | 0.91 | ADRB3 (0.40) | ADRB3ADRA2BADRA2CCYP3A4MAPT | |
| SCHEMBL13059010 | 0.91 | ADRB3 (0.43) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL3065116 | 0.90 | ADRB3 (0.42) | ADRB3ADRA2BADRA2CCYP3A4BACE1 | |
| SCHEMBL3787948 | 0.89 | ADRB3 (0.41) | ADRB3ADRA2BADRA2CCYP3A4BACE1 | |
| SCHEMBL3787952 | 0.89 | ADRB3 (0.41) | ADRB3ADRA2BADRA2CCYP3A4BACE1 | |
| SCHEMBL3787944 | 0.89 | ADRB3 (0.41) | ADRB3ADRA2BADRA2CCYP3A4BACE1 | |
| SCHEMBL8243274 | 0.89 | ADRB3 (0.44) | ADRB3ADRA2BADRA2CCYP3A4BACE1 | |
| SCHEMBL7926483 | 0.89 | ADRB3 (0.40) | ADRB3ADRA2BADRA2CCYP3A4BACE1 | |
| SCHEMBL10010275 | 0.87 | ADRB3 (0.34) | ADRB3ADRA2BADRA2CBACE1REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150119319-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ABBVIE INC. | 2015-04-30 | — | — | US | disclosed |
| US-8937041-B2 | Macrocyclic hepatitis C serine protease inhibitors | ABBVIE, INC. (US) | 2015-01-20 | — | — | US | disclosed |
| EP-2658859-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2013-11-06 | — | — | EP | disclosed |
| US-20120172291-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ABBVIE INC. | 2012-07-05 | — | — | US | disclosed |
| WO-2012092409-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARARMACEUTICALS, INC (US) | 2012-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119319-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | TMPRSS15, PRSS1, SPINT2 | ADRB3 3516/4885ADRA2B 4329/4885ADRA2C 3375/4885 |
| US-20120172291-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | TMPRSS15, PRSS1, SPINT2 | ADRB3 3516/4885ADRA2B 4329/4885ADRA2C 3375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.